GB202010276D0 - PCSK9 antagonist - Google Patents

PCSK9 antagonist

Info

Publication number
GB202010276D0
GB202010276D0 GBGB2010276.0A GB202010276A GB202010276D0 GB 202010276 D0 GB202010276 D0 GB 202010276D0 GB 202010276 A GB202010276 A GB 202010276A GB 202010276 D0 GB202010276 D0 GB 202010276D0
Authority
GB
United Kingdom
Prior art keywords
pcsk9 antagonist
pcsk9
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2010276.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Argonaute RNA Ltd
Original Assignee
Argonaute RNA Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argonaute RNA Ltd filed Critical Argonaute RNA Ltd
Priority to GBGB2010276.0A priority Critical patent/GB202010276D0/en
Publication of GB202010276D0 publication Critical patent/GB202010276D0/en
Priority to JP2022552336A priority patent/JP2023519140A/en
Priority to CA3167849A priority patent/CA3167849A1/en
Priority to CN202180013447.0A priority patent/CN115066498A/en
Priority to EP21712703.4A priority patent/EP4081642A1/en
Priority to PCT/EP2021/056540 priority patent/WO2021185765A1/en
Priority to US17/908,225 priority patent/US20230183694A1/en
Priority to GB2103594.4A priority patent/GB2594788B/en
Ceased legal-status Critical Current

Links

GBGB2010276.0A 2020-03-16 2020-07-03 PCSK9 antagonist Ceased GB202010276D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB2010276.0A GB202010276D0 (en) 2020-07-03 2020-07-03 PCSK9 antagonist
JP2022552336A JP2023519140A (en) 2020-03-16 2021-03-15 PCSK9 antagonist
CA3167849A CA3167849A1 (en) 2020-03-16 2021-03-15 Antagonist of pcsk9
CN202180013447.0A CN115066498A (en) 2020-03-16 2021-03-15 Antagonists of PCSK9
EP21712703.4A EP4081642A1 (en) 2020-03-16 2021-03-15 Antagonist of pcsk9
PCT/EP2021/056540 WO2021185765A1 (en) 2020-03-16 2021-03-15 Antagonist of pcsk9
US17/908,225 US20230183694A1 (en) 2020-03-16 2021-03-15 Antagonist of pcsk9
GB2103594.4A GB2594788B (en) 2020-03-16 2021-03-16 Antagonist of PCSK9

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2010276.0A GB202010276D0 (en) 2020-07-03 2020-07-03 PCSK9 antagonist

Publications (1)

Publication Number Publication Date
GB202010276D0 true GB202010276D0 (en) 2020-08-19

Family

ID=72050566

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2010276.0A Ceased GB202010276D0 (en) 2020-03-16 2020-07-03 PCSK9 antagonist

Country Status (1)

Country Link
GB (1) GB202010276D0 (en)

Similar Documents

Publication Publication Date Title
IL279363A (en) Pcsk9 antagonist compounds
ZA202202362B (en) Kras g12d inhibitors
IL289534A (en) Parp1 inhibitors
IL304534A (en) Kras g12c inhibitors
GB2594788B (en) Antagonist of PCSK9
EP3810129A4 (en) Pcsk9 antagonist bicyclo-compounds
IL289754A (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
EP4114862A4 (en) Anti-ccr8 agents
EP4076492A4 (en) Pcsk9 antagonist compounds
GB2585278B (en) Apolipoprotein B Antagonist
GB201905552D0 (en) Antagonists
IL289252A (en) Ep2 antagonist
IL300211A (en) Antagonist compounds
GB202019622D0 (en) Antagonist compounds
EP4317153A4 (en) Abhd6 antagonist
GB202010276D0 (en) PCSK9 antagonist
GB202207246D0 (en) PCSK9 antagonist
GB202113104D0 (en) Antagonist of pcsk9
GB202020553D0 (en) Antagonist of pcsk9
GB202013998D0 (en) Antagonist of pcsk9
GB202003756D0 (en) Antagonist of PCSK9
GB202000906D0 (en) Antagonist
GB201910526D0 (en) Antagonist
GB201909500D0 (en) Antagonist
GB202019922D0 (en) Antagonist compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)